Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
ReSPECT-GBM
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT01906385 ↗
- Recruiting
- Cerenome
- Focused
We haven't built an HCP commentary report on ReSPECT-GBM yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ReSPECT-GBM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Arms
- 186Rhenium Liposome Treatment · Experimental
- Enrollment
- 55 (estimated)
- Primary outcomes
- Phase 1: Maximum Tolerated Dose
- Phase 2: Overall Survival
- Sponsor
- Cerenome with National Cancer Institute (NCI)
- Start
- Jun 3, 2015
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT01906385 · updated Oct 15, 2026
Publications
linked from the registry- Wu C, Hormuth DA 2nd, Christenson CD, Woodall RT, Abdelmalik MRA, Phillips WT, Hughes TJR, Brenner AJ, Yankeelov TE. Image-guided patient-specific optimization of catheter placement for convection-enhanced nanoparticle delivery in recurrent glioblastoma. Comput Biol Med. 2024 Sep;179:108889. doi: 10.1016/j.compbiomed.2024.108889. Epub 2024 Jul 19. PubMed 39032243